Start Over

The path to the standardization of PTH

Authors :: Candice Z. Ulmer
Konstantinos Makris
Annemieke C. Heijboer
Etienne Cavalier
Samuel Vasikaran
Harjit Pal Bhattoa
Endocrinology Laboratory
AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
Laboratory Medicine
Amsterdam Gastroenterology Endocrinology Metabolism
Amsterdam Reproduction & Development (AR&D)
Source :: Cavalier, E, Vasikaran, S, Bhattoa, H P, Heijboer, A C, Makris, K & Ulmer, C Z 2021, ' The path to the standardization of PTH : Is this a realistic possibility? a position paper of the IFCC C-BM ', Clinica Chimica Acta, vol. 515, pp. 44-51 . https://doi.org/10.1016/j.cca.2020.12.022, Clinica chimica acta; international journal of clinical chemistry, 515, 44-51. Elsevier, Clinica Chimica Acta, 515, 44-51. Elsevier, Clin Chim Acta
Publication Year :: 2021
Abstract: Parathyroid hormone (PTH) determination is of greatest importance for patients suffering from parathyroid gland disorders and for the follow-up of bone turnover in patients suffering from chronic kidney disease (CKD). Two generations of PTH assays are simultaneously present on the market for PTH quantification. As these assays are not yet standardized, this results in a significant level of confusion in the care of CKD patients. One key objective of the IFCC Committee for Bone Metabolism is to improve this situation. In this position paper, we will highlight the current state of PTH testing and propose a pathway to ultimately overcome issues resulting from PTH assay variability.